Coping styles and their influence on outcomes in Parkinson’s disease
Objective: To understand the associations between coping styles and various clinical symptoms and outcomes in patients with Parkinson's disease (PD). Background: The diagnosis of a…Overlapping corticobasal syndromes: The many faces of the Armstrong criteria
Objective: To evaluate the prevalence and clinical presentation of corticobasal variants listed in the new Armstrong criteria, exploring their overlap with progressive supranuclear palsy (PSP),…Computer uses and difficulties in Parkinson’s disease
Objective: The purpose of the study is to assess computer use habits and difficulties of patients (pts) with Parkinson's disease (PD). These are preliminary data…Frequency of falls in nursing homes for neurodegenerative diseases
Objective: This study aimed to identify the frequency and characteristics (causes, circumstances, consequences), of falls that occurred at Campus Neurologico Senior from Oct 2013 until…A new test for the measuring hand functions in Parkinson’s disease: Psychometric evaluation of the squares test
Objective: The aim of the study was to determine reliability and validity of the ST in PD. Background: Parkinson's disease (PD) is affected hand functions…Engrailed enhances dopamine synthesis in healthy dopaminergic neurons
Objective: The aim of the present study was to further elucidate the role of Engrailed in dopamine neurotransmission. Background: Engrailed1 and Engrailed2, collectively Engrailed, are…Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease
Objective: Understanding the drug effects with respect to various ion channels on subthalamic nucleus (STN) cells is the key to safety pharmacology assessment. Here our…Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…
- « Previous Page
- 1
- …
- 330
- 331
- 332
- 333
- 334
- …
- 405
- Next Page »